TNXP Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
EN
07/10/2020

Underlying

TNXPTonix Pharmaceuticals Holding Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tonix Pharmaceuticals Holding Corp

 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokineti...

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years The sublingual TONMYA tablet containing a basifying agent achieved the design objectives of rapid transmucosal absorption and bypassing first-pass liver metabolism TONMYA was designed to decrea...

9h / 10m 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 America...

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, being held March 5–8, 2026, in Salt Lake City, Utah. A copy of the ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market t...

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the Company’s existin...

March 3, 2026 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals to Participate in Two Investor Conferences in Ma...

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026: TD Cowen 46th Annual Healthcare ConferenceCompany PresentationPresenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate: Wednesday March 4, 2026Place: Boston Marriott Copley Plac...

February 25, 2026 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyc...

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite Treatment was well tolerated with minimal effects on weight or blood pressure CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- T...

January 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch